ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the mechanism of
methodsA non-pregnant female SD rat model of mammary hyperplasia was established by intramuscular injections of estradiol benzoate (0.5 mg/kg) and progesterone (5 mg/kg). With untreated rats as the control group, the rat models were treated with saline (model group) or low-, medium- or high-dose XHG daily gavage, or with high-dose XHG plus oral administration of GS-444217. After the treatments, nipple height, diameter, and uterine index of the rats were measured, and histological changes in the mammary tissue were observed with HE staining. The expressions of Ki-67 and caspase-3 protein in the mammary tissue were detected using immunohistochemistry, and mammary epithelial cell apoptosis was examined using TUNEL staining. Serum levels of E2, P, PRL, FSH, IL-1β, and TNF-α were detected using ELISA, and the expressions of ASK1/MKK4/JNK and apoptosis-related proteins were analyzed using RT-qPCR and Western blotting.
resultsCompared with the normal control rats, the rats in the model group showed significantly increased mammary diameter, nipple height, and uterine index with obvious acinar hyperplasia, ductal dilation, and inflammatory cell infiltration in the mammary tissue. The rat models also showed significantly increased Ki-67 expression and serum levels of E2, P, PRL, FSH, IL-1β and TNF-α, markedly increased Bcl-2 expression, and lowered protein levels of p-ASK1/ASK1, p-MKK4/MKK4, p-JNK/JNK, caspase-3, and Bax in the mammary tissue. Treatment with XHG significantly reversed these changes in a dose-dependent manner. Treatment with GS-444217 significantly attenuated the ameliorative effect of high-dose XHG on mammary hyperplasia in the rat models.
conclusionsXHG alleviates mammary hyperplasia in rats by promoting apoptosis of hyperplastic mammary epithelial cells
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.